Several reports show that ATF5 mediates the survival of breast cancer, glioma, and transformed myeloid cells but is not required for the survival of non-transformed astrocytes, fibroblasts, and breast epithelial cells (16, 19, 22), thus enabling specificity of ATF5 clinical targeting. The gene discussed is ATF5; the disease is glioma.